Aristotle University Of Thessaloniki (AUTH)
Installation of hybrid cyclotrons in remote regions: development of a tailored techno-economic cost-effectiveness model
Abstract
dc:descriptionPositron Emission Tomography (PET) has become an essential component of modern oncological management, enabling accurate staging, treatment planning and response assessment across a wide range of malignancies. However, access to PET imaging remains uneven, particularly in geographically isolated regions where reliance on mainland radiopharmaceutical delivery introduces logistical fragility, increased costs and potential delays in care. This thesis investigates the feasibility, economic implications and health impact of local radiopharmaceutical production in such settings, using Corsica as a principal case study and extending the analysis to other European island regions. The work combines complementary methodological approaches to address both economic and clinical dimensions of PET deployment. First, a detailed cost-minimisation analysis is performed over a 20-year time horizon to compare three competing supply models: continued mainland delivery of PET radiopharmaceuticals, local PET-only cyclotron production and hybrid cyclotron production supporting both PET and Single Photon Emission Computed Tomography (SPECT) activity. The analysis incorporates capital investment, fixed and variable operational costs, logistics, population-adjusted demand forecasts, purchasing power parity corrections and sensitivity analyses. Results demonstrate that delivery-based models are structurally inefficient in island regions, while local production —particularly hybrid cyclotron solutions— consistently emerges as the least costly long-term strategy, with substantial discounted savings in most scenarios. Beyond economic modelling, the thesis presents an original assessment of the population-level health impact of PET availability. Using a difference-in-differences framework applied to French departmental mortality data and PET installation timelines, the analysis estimates the causal effect of PET introduction on cancer mortality. A statistically significant reduction in mortality is identified for tracheal, bronchial and lung cancers, amounting to approximately 2,72 fewer deaths per 100.000 inhabitants per year. This effect is robust, supported by parallel-trend and event-study analyses, and specific to lung cancer, consistent with the clinical role of PET in accurate staging and treatment selection. This mortality reduction constitutes the primary original scientific contribution of the thesis.To integrate clinical outcomes with economic evaluation, the estimated reduction in lung cancer mortality is translated into Quality-Adjusted Life Years (QALYs) and monetised using standard European willingness-to-pay thresholds. Applied to Corsica, the empirical effect corresponds to approximately 4,62 avoided lung cancer deaths per year, yielding around 4,51 QALYs gained annually. Depending on the value assigned to a QALY, this represents an annual health benefit between 90.200 € and 225.500 €, and a discounted 20-year benefit between 1,8 and 4,5 million €. While conservative and limited to lung cancer alone, these estimates demonstrate that PET availability generates measurable population-level health gains in addition to substantial cost savings. Taken together, the results of this thesis show that local radiopharmaceutical production in geographically isolated regions is both economically viable and clinically meaningful. The findings support a broader view of diagnostic infrastructure as a determinant of health outcomes and equity, rather than merely a technical or logistical resource. By integrating economic modelling, empirical mortality analysis and QALY-based valuation, this work provides a comprehensive framework for evaluating local radiopharmaceutical production deployment and contributes evidence relevant to health economics and health-care policy.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Melidis, Christos
- Μελίδης, Χρήστος
Subjects
dc:subject × 10Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/62479